Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Killed whole cell oral cholera vaccine
- Development stage
- Phase 2
- Lead developer
- International Vaccine Institute
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Killed whole cell oral cholera vaccines (kOCVs) are inactivated vaccines containing killed *Vibrio cholerae* bacteria (typically serogroups O1 and O139), administered orally to prevent cholera. These vaccines stimulate the intestinal immune response to limit colonization of *V. cholerae* in the gut following exposure. They are used for both outbreak control and routine immunization in endemic areas and have demonstrated safety and efficacy in multiple clinical trials. Notable formulations include Dukoral (which also contains recombinant B subunit of the cholera toxin), Shanchol, Euvichol, and Euvichol-Plus; all are prequalified by WHO for global use[3][5][6][8]. The primary indication is prevention of disease caused by *Vibrio cholerae*.
- Brand names
- DukoralShancholEuvicholEuvichol-PlusmORC-Vax
- Other names
- kOCVkilled oral cholera vaccineinactivated whole-cell oral cholera vaccine
Beyond the preview
Go deeper on Killed whole cell oral cholera vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Killed whole cell oral cholera vaccine.